Last reviewed · How we verify
ABT-494
ABT-494 is a JAK1 inhibitor that selectively blocks Janus kinase 1 signaling to reduce inflammatory cytokine production and immune cell activation.
ABT-494 is a JAK1 inhibitor that selectively blocks Janus kinase 1 signaling to reduce inflammatory cytokine production and immune cell activation. Used for Rheumatoid arthritis, Inflammatory bowel disease.
At a glance
| Generic name | ABT-494 |
|---|---|
| Also known as | Upadacitinib, RINVOQ |
| Sponsor | AbbVie |
| Drug class | JAK1 inhibitor |
| Target | JAK1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
ABT-494 preferentially inhibits JAK1 over other JAK family members, which are key intracellular signaling proteins involved in inflammatory and immune responses. By blocking JAK1, the drug suppresses the production of pro-inflammatory cytokines and reduces pathogenic immune cell differentiation and activation. This mechanism is intended to treat autoimmune and inflammatory diseases with potentially improved selectivity compared to pan-JAK inhibitors.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease
Common side effects
- Infections
- Elevated lipid levels
- Gastrointestinal disorders
Key clinical trials
- A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (PHASE3)
- A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis (PHASE3)
- Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (PHASE3)
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-494 CI brief — competitive landscape report
- ABT-494 updates RSS · CI watch RSS
- AbbVie portfolio CI